Conyers acted as special legal counsel in the Cayman Islands to Sino Biopharmaceutical Limited in connection with its issuance of €750 million zero coupon convertible bonds due 2025.
Sino Biopharmaceutical Limited is a leading pharmaceutical conglomerate in China. It belongs to the Charoen Pokphand Group and is headquartered in Hong Kong and Beijing. Its business includes researching, developing, producing, and selling biopharmaceutical products. It was listed on the Hong Kong Stock Exchange in 2000 (Stock code: 1177).
Partner Anna Chong of Conyers’ Hong Kong office advised on the matter working alongside King & Wood Mallesons, Linklaters and Tian Yuan Law Firm.